// App-Quantinova.ai

: Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Researchers

Presenter

  • Matthew Mei

Principal Investigators

  • Sairah Ahmed

  • Amer Beitinjaneh

  • Natalie S. Grover

  • Carlos A. Ramos

  • Khong Bee Kang

  • Paul I. Nadler

  • Aung Myo

  • Ivan D. Horak

  • Helen E. Heslop

Medical Centers

  • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

  • Department of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX

  • Division of Lymphoma, City of Hope Medical Center, Duarte, CA

  • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX

  • Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL

Locations

  • Singapore

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Cluster of Differentiation 30

  • Apparent diffusion coefficient

Drug/Treatment

  • brentuximab vedotin

  • Adcetris

  • Bendamustine

  • fludarabine tablet

  • Nivolumab

Outcome

  • N/A

Study Design

  • Safety

  • Single Arm

  • Multicenteric

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved